Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature
RI Skotheim, M Bogaard, KT Carm, U Axcrona… - … et Biophysica Acta (BBA …, 2024 - Elsevier
Prostate cancer is unique compared to other major cancers due to the presence of multiple
primary malignant foci in the majority of patients at the time of diagnosis. Each malignant …
primary malignant foci in the majority of patients at the time of diagnosis. Each malignant …
Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
A Nurminen, S Jaatinen, S Taavitsainen, G Högnäs… - Genome medicine, 2023 - Springer
Abstract Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to
therapies such as androgen deprivation. Such heterogeneity can be deciphered in the …
therapies such as androgen deprivation. Such heterogeneity can be deciphered in the …
Newly developed MEIS inhibitor selectively blocks MEISHigh prostate cancer growth and induces apoptosis
Prostate cancer (PCa) is the second most diagnosed cancer in males. Understanding the
molecular mechanism and investigation of novel ways to block PCa growth or metastasis …
molecular mechanism and investigation of novel ways to block PCa growth or metastasis …
[PDF][PDF] 近距离放疗治疗≤ cT3 期前列腺癌的远期疗效及影响预后的危险因素
王增增， 李月明， 徐勇 - 临床泌尿外科杂志, 2024 - lcmw.whuhzzs.com
近距离放疗治疗≤cT3期前列腺癌的远期疗效及影响预后的危险因素 Page 1 2024年 临床泌尿
外科杂志 39卷4期 JClinUrol(China) 引用本文:王增增,李月明,徐勇.近距离放疗治疗≤cT3期 …
外科杂志 39卷4期 JClinUrol(China) 引用本文:王增增,李月明,徐勇.近距离放疗治疗≤cT3期 …
Clinical outcomes and predictors of ≤cT3 prostate cancer treated by 125I low-dose-rate prostate brachytherapy
W Zengzeng, LI Yueming, XU Yong - J Clin Urol, 2024 - lcmwen.whuhzzs.com
Clinical outcomes and predictors of ≤cT3 prostate cancer treated by <sup>125</sup>I low-dose-rate
prostate brachytherapy Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …
prostate brachytherapy Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …
[引用][C] Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue.
K Axcrona, K Aas, U Axcrona, RI Skotheim - European Urology, 2022 - europepmc.org
Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …